ArticleCell transplantation2019
The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials.
Article in Cell transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Helicobacter pylori infection and risk of multiple sclerosis: an updated meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Efficacy of diet on fatigue, quality of life and disability status in multiple sclerosis patients: rapid review and meta-analysis of randomized controlled trials.BMC neurology · 2022Pooled it
- The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial.Scientific reports · 2023Trial
- Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis.International journal of molecular sciences · 2021Trial
- Proportionality-based association metrics in count compositional data.NAR genomics and bioinformatics · 2026Article
- Pharmacomicrobiomics: From Host-Microbiome-Drug Interactions to Clinical Translation in Precision Medicine.Metabolites · 2026Review
- Multikingdom microbiome-based machine learning enables multiple sclerosis diagnosis.NPJ biofilms and microbiomes · 2026Article
- Impact of Probiotics, Prebiotics and Synbiotics Supplementation in Chronic Kidney Disease: A Comprehensive Review of Clinical Trials.Nutrients · 2026Review
- Anti‑obesity Effects of Lactiplantibacillus plantarum ZNFL-1 by Modulating Gut Microbiota and Lipid Metabolism in High‑Fat Diet‑Induced Mice.Probiotics and antimicrobial proteins · 2026Article
- Silent Intruders: The Gut Virome in Brain Aging and Cognitive Decline.Pathogens (Basel, Switzerland) · 2026Review
- Bioactive Phytochemicals in Experimental Models of Multiple Sclerosis: Mechanisms, Efficacy, and Translational Potential.Nutrients · 2026Review
- The Microbiome-Neurodegeneration Interface: Mechanisms, Evidence, and Future Directions.Cells · 2026Review
- Review
- Unraveling multiple sclerosis: a hidden interaction between intestinal microbiota and host lipid metabolism.Gut microbes · 2025Review
- The gut-eye axis in blinding eye diseases: microbiota-driven immune dysregulation and immunomodulatory therapies.International ophthalmology · 2025Review
- Dysbiosis and Therapeutic Modulation of the Gut Microbiota in Multiple Sclerosis: A Narrative Review.Health science reports · 2025Article
- Decoding the Gut Microbiota in Multiple Sclerosis Using Nanopore Long-Read Sequencing: Insights into Disease Severity and Subtypes.Molecular neurobiology · 2025Article
- Precision Nutrition and Gut-Brain Axis Modulation in the Prevention of Neurodegenerative Diseases.Nutrients · 2025Review
- Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets.Molecular biomedicine · 2025Review
- The Microbiota-Gut-Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders.CNS neuroscience & therapeutics · 2025Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical studies carried out in recent years that aimed to evaluate the composition of the microbiota in patients with relapsing-remitting MS (RR-MS). We also report what is available in the literature regarding the effectiveness of fecal microbiota transplantation and the role of the diet in restoring the intestinal bacterial population. Studies report that patients with RR-MS have a microbiota that, compared with healthy controls, has higher amounts of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.